| 000 | 01727 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513183552.0 | ||
| 264 | 0 | _c19990608 | |
| 008 | 199906s 0 0 eng d | ||
| 022 | _a0360-3016 | ||
| 024 | 7 |
_a10.1016/s0360-3016(99)00051-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKamath, S S | |
| 245 | 0 | 0 |
_aThe impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. _h[electronic resource] |
| 260 |
_bInternational journal of radiation oncology, biology, physics _cJun 1999 |
||
| 300 |
_a563-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aActuarial Analysis |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Non-Hodgkin _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 |
_aProcarbazine _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRadiotherapy Dosage |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aMarcus, R B | |
| 700 | 1 | _aLynch, J W | |
| 700 | 1 | _aMendenhall, N P | |
| 773 | 0 |
_tInternational journal of radiation oncology, biology, physics _gvol. 44 _gno. 3 _gp. 563-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0360-3016(99)00051-6 _zAvailable from publisher's website |
| 999 |
_c10306954 _d10306954 |
||